Echinacea Angustifolia (AnxioCalm) in Anxiety

Generalized Anxiety Disorder Clinical Trial

Official title:

A Phase 2 Randomized, Double-Blind, Parallel-Group, Placebo Controlled Fixed-Dose Study of Echinacea Angustifoliae Root Extract (AnxioCalm) in Healthy Subjects With Subthreshold Symptoms of Anxiety

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03463018
• Other study ID #: EP-1003
• Secondary ID: EP-02-2017
• Status: Terminated
• Phase: Phase 2
• Start date: June 6, 2018
• Est. completion date: December 15, 2021

Study information

• Verified date: March 2022
• Source: EuroPharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms. Half the participants will receive Echinacea angustifolia and half will receive placebo.

Description:

Echinacea angustifolia root extract (AnxioCalm), standardized for the content of echinacoside and its alkamide profile, is intended to be used for 'amelioration of sub-threshold and mild anxiety which are risk factors in the development of Generalized Anxiety Disorder (GAD) and depression' in symptomatic people 'who are not eligible for anxiolytic medication.' Existing medical interventions, which require long periods of repeated administration, have significant safety concerns.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 100
• Est. completion date: December 15, 2021
• Est. primary completion date: October 3, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women 18 years of age (all races and ethnicity)

• Meet Diagnostic and Statistical Manual of Mental Disorders (DSM IV) any criteria for Generalized Anxiety Disorder (GAD from 5 to 9)

• mild to moderate symptom severity on the Beck Anxiety Inventory (BAI from 8 to 15)

• Hamilton Anxiety Rating Scale (HAM-A) score from 14 to 17

• Hospital Anxiety and Depression Scale (HADS-A) [hospital anxiety and depression scale
• anxiety subscale] - 8-10

• Participants score 45-57 points of above on either the state or trait anxiety subscale of the State and Trait Anxiety Inventory of Speilberger (STAI)

• Able to understand and provide signed informed consent

• Able to participate in a 5-week study

Exclusion Criteria:

• Any diagnosed DSM-IV Axis II disorder

• Current DSM IV Axis I diagnosis of Major Depressive Disorder in the 6 month that precede the study. [to exclude confounding psychiatric factors]

• Danger of suicidality

• Treatment with Echinacea preparations in the 3 month that precede the study

• Psychotropic medication (especially anxiolytics) in the 3 month that precede the study

• Psychotherapy in the 3 month that precede the study

• Allergic reactions to plants of the Asteraceae family (Echinacea species, etc.)

• Treatment for AIDS or cancer

• Pregnant or lactating women

• Unstable medical condition (e.g., hypothyroidism, hypertension, myocardial infarction within 1 month, neoplastic condition)

• Alcohol or drug dependence within 3 months

• Allergy to Echinacea preparation

• Allergy to plants of the Asteraceae family (e.g., ragweed, asters, chrysanthemum)

• Allergy to mugwort, radioallergosorbent test (RAST), or birch tree pollen Concurrent tranquilizer, antidepressant or mood stabilizer therapy;

• Subjects receiving anti-anxiety medication (e.g., benzodiazepine, venlafaxine, buspirone, or SSRI)

• Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, Kava kava)

• Women of child-bearing potential not willing to employ a medically proven form of contraception (e.g., condoms, oral contraceptives, etc)

• Any other condition that precludes participation according to the judgement of the investigator

Related Conditions & MeSH terms

• Anxiety Disorders
• Generalized Anxiety Disorder

Intervention

Dietary Supplement:
• Echinacea angustifolia
20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
• Placebo
Placebo tablet containing matching excipients to the active intervention

Locations

Country	Name	City	State
Georgia	Simon Skechinashvili University Hospital	Tbilisi

Sponsors (2)

Lead Sponsor	Collaborator
EuroPharma, Inc.	Simon Khechinashvili University

Country where clinical trial is conducted

Georgia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Anxiety Rating (HAM-A)	The Hamilton Anxiety Rating Scale (HAM-A) is a physician rating scale consisting of 14 items measuring psychic and somatic anxiety. Each item is scored on a scale of 0 (none) to 4 (severe) where a total score of 14-17 = Mild Anxiety, 18-24 = Moderate Anxiety, 25-30 = Severe Anxiety. The primary outcome is the change over time in the baseline HAM-A score rating for AnxioCalm versus placebo.	14 days
Primary	State-Trait Anxiety Inventory (STAI)	The State-Trait Anxiety Inventory (Form Y, 6 item) is a six item patient rating scale consisting of anxiety present and anxiety absent items. Each item is rated from 1 (not at all) to 4 (very much). For scoring, positive items (calm, relaxed, content) are reverse scored [1=4, 2=3, 3=2, 4=1], the six scores are totaled, and multiplied by 20/6. A normal score is approximately 34-36.The primary outcome is the change over time in the baseline STAI score for AnxioCalm versus placebo.	14 days